专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07435724B2 Degradation-resistant mononucleoside phosphate compounds 失效
标题翻译：降解抗性单核苷磷酸化合物
公开(公告)号：US07435724B2
公开(公告)日：2008-10-14
申请号：US11285221
申请日：2005-11-21
申请人： James G. Douglass, III , Benjamin R. Yerxa , Sammy R. Shaver , Ward M. Peterson , Edward G. Brown , Christopher S. Crean , José L. Boyer
发明人： James G. Douglass, III , Benjamin R. Yerxa , Sammy R. Shaver , Ward M. Peterson , Edward G. Brown , Christopher S. Crean , José L. Boyer
IPC分类号： A01N43/04 , A61K31/70
CPC分类号： C07H19/10 , C07H19/20
摘要： The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.
摘要翻译：本发明涉及具有二核苷酸药物益处的单核苷磷酸化合物。这些单核苷酸磷酸酯可以由已经通过在聚磷酸酯单核苷酸的末端磷酸酯上连接降解抗性取代基而被修饰的单核苷酸制成。通过连接该降解抗性的取代基，降解的稳定性与某些二核苷酸的匹配或超过某些二核苷酸。本发明的单核苷磷酸化合物可用于预防和治疗与血小板聚集有关的上皮组织疾病或疾病或病症。

2. 发明授权

US07084128B2 Method for reducing intraocular pressure 失效
公开(公告)号：US07084128B2
公开(公告)日：2006-08-01
申请号：US10347255
申请日：2003-01-15
申请人： Benjamin R. Yerxa , Robert Plourde, Jr. , Edward G. Brown , Ward M. Peterson
发明人： Benjamin R. Yerxa , Robert Plourde, Jr. , Edward G. Brown , Ward M. Peterson
IPC分类号： A61K31/70 , C07H21/00
CPC分类号： C07H19/20 , Y10S514/912 , Y10S514/913
摘要： The present invention is directed to a method of reducing intraocular pressure. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a purinerginic receptor ligand, which is a mononucleoside polyphosphate or dinucleoside polyphosphate defined by general Formula I. The method of the present invention is useful in the treatment or prevention of ocular hypertension, such as glaucoma, including primary and secondary glaucoma. The method can be used alone to reduce intraocular pressure. The method can also be used in conjunction with other therapeutic agents or adjunctive therapy commonly used to treat glaucoma to enhance the therapeutic effect of reducing the intraocular pressure.

3. 发明授权

US07939510B2 Di(uridine 5′-)tetraphosphate and salts thereof 有权
标题翻译：二（尿苷5' - ）四磷酸及其盐
公开(公告)号：US07939510B2
公开(公告)日：2011-05-10
申请号：US12430684
申请日：2009-04-27
申请人： Benjamin R. Yerxa , Edward G. Brown
发明人： Benjamin R. Yerxa , Edward G. Brown
IPC分类号： A61K31/70
CPC分类号： A61K31/7048 , A61K31/7068 , A61K31/7072 , A61K31/7076 , C07H19/10 , C07H19/20 , C07H21/00 , Y10S514/851
摘要： The present invention are directed to P1,P4-di(uridine 5′-)tetraphosphate, tetra-alkali metal salts such as tetrasodium, tetralithium, tetrapotassium, and mixed tetra-alkali metal cations thereof. The tetra alkali metal salts of P1,P4-di(uridine 5′-)tetraphosphate are water-soluble, nontoxic, and easy to handle during manufacture. These tetra-monovalent alkali metal salts are more resistant to hydrolysis than the mono-, di-, or tri-acid salts, therefore, they provide an improved stability and a longer shelf life for storage. The present invention also provides methods for the synthesis of P1,P4-di(uridine 5′-)tetraphosphate, and its pharmaceutically acceptably acceptable salts thereof, and demonstrates the applicability to the production of large quantities. The methods substantially reduce the time required to synthesize diuridine tetraphosphate, for example, to three days or less.
摘要翻译：本发明涉及P1，P4-二（尿苷5'-）四磷酸盐，四碱金属盐如四钠，四锂，四钾及其混合四碱金属阳离子。 P1，P4-二（尿苷5' - ）四磷酸的四碱金属盐是水溶性的，无毒的，在制造过程中易于处理。这些四价一价碱金属盐比单 - ，二 - 或三 - 酸盐更耐水解，因此，它们提供了改进的稳定性和更长的储存期限。本发明还提供了合成P1，P4-二（尿苷5' - ）四磷酸及其药学上可接受的盐的方法，并且证明了对大量生产的适用性。所述方法基本上减少了合成二脯氨酸四磷酸酯所需的时间，例如为3天或更短。

4. 发明授权

US07528119B2 Di(uridine 5′-)tetraphosphate and salts thereof 有权
标题翻译：二（尿苷5' - ）四磷酸及其盐
公开(公告)号：US07528119B2
公开(公告)日：2009-05-05
申请号：US11486497
申请日：2006-07-14
申请人： Benjamin R. Yerxa , Edward G. Brown
发明人： Benjamin R. Yerxa , Edward G. Brown
IPC分类号： A61K31/70
CPC分类号： A61K31/7048 , A61K31/7068 , A61K31/7072 , A61K31/7076 , C07H19/10 , C07H19/20 , C07H21/00 , Y10S514/851
摘要： The present invention are directed to P1,P4-di(uridine 5′-)tetraphosphate, tetra-alkali metal salts such as tetrasodium, tetralithium, tetrapotassium, and mixed tetra-alkali metal cations thereof. The tetra alkali metal salts of P1,P4-di(uridine 5′-)tetraphosphate are water-soluble, nontoxic, and easy to handle during manufacture. These tetra-monovalent alkali metal salts are more resistant to hydrolysis than the mono-, di-, or tri-acid salts, therefore, they provide an improved stability and a longer shelf life for storage. The present invention also provides methods for the synthesis of P1,P4-di(uridine 5′-)tetraphosphate, and its pharmaceutically acceptably acceptable salts thereof, and demonstrates the applicability to the production of large quantities. The methods substantially reduce the time required to synthesize diuridine tetraphosphate, for example, to three days or less.
摘要翻译：本发明涉及P1，P4-二（尿苷5'-）四磷酸盐，四碱金属盐如四钠，四锂，四钾及其混合四碱金属阳离子。 P1，P4-二（尿苷5' - ）四磷酸的四碱金属盐是水溶性的，无毒的，在制造过程中易于处理。这些四价一价碱金属盐比单 - ，二 - 或三 - 酸盐更耐水解，因此，它们提供了改进的稳定性和更长的储存期限。本发明还提供了合成P1，P4-二（尿苷5' - ）四磷酸及其药学上可接受的盐的方法，并且证明了对大量生产的适用性。所述方法基本上减少了合成二脯氨酸四磷酸酯所需的时间，例如为3天或更短。

5. 发明申请

US20090326050A1 DI(URIDINE 5'-)TETRAPHOSPHATE AND SALTS THEREOF 有权
标题翻译： DI（尿苷5' - ）四磷酸酯及其盐
公开(公告)号：US20090326050A1
公开(公告)日：2009-12-31
申请号：US12430684
申请日：2009-04-27
申请人： Benjamin R. Yerxa , Edward G. Brown
发明人： Benjamin R. Yerxa , Edward G. Brown
IPC分类号： A61K31/711 , A61P27/02
CPC分类号： A61K31/7048 , A61K31/7068 , A61K31/7072 , A61K31/7076 , C07H19/10 , C07H19/20 , C07H21/00 , Y10S514/851
摘要： The present invention are directed to P1,P4-di(uridine 5′-)tetraphosphate, tetra-alkali metal salts such as tetrasodium, tetralithium, tetrapotassium, and mixed tetra-alkali metal cations thereof. The tetra alkali metal salts of P1,P4-di(uridine 5′-)tetraphosphate are water-soluble, nontoxic, and easy to handle during manufacture. These tetra-monovalent alkali metal salts are more resistant to hydrolysis than the mono-, di-, or tri-acid salts, therefore, they provide an improved stability and a longer shelf life for storage. The present invention also provides methods for the synthesis of P1,P4-di(uridine 5′-)tetraphosphate, and its pharmaceutically acceptably acceptable salts thereof, and demonstrates the applicability to the production of large quantities. The methods substantially reduce the time required to synthesize diuridine tetraphosphate, for example, to three days or less.
摘要翻译：本发明涉及P1，P4-二（尿苷5'-）四磷酸盐，四碱金属盐如四钠，四锂，四钾及其混合四碱金属阳离子。 P1，P4-二（尿苷5' - ）四磷酸的四碱金属盐是水溶性的，无毒的，在制造过程中易于处理。这些四价一价碱金属盐比单 - ，二 - 或三 - 酸盐更耐水解，因此，它们提供了改进的稳定性和更长的储存期限。本发明还提供了合成P1，P4-二（尿苷5' - ）四磷酸及其药学上可接受的盐的方法，并且证明了对大量生产的适用性。所述方法基本上减少了合成二脯氨酸四磷酸酯所需的时间，例如为3天或更短。

6. 发明授权

US07612047B2 Degradation-resistant mononucleoside phosphate compounds 失效
标题翻译：降解抗性单核苷磷酸化合物
公开(公告)号：US07612047B2
公开(公告)日：2009-11-03
申请号：US12208265
申请日：2008-09-10
申请人： James G. Douglass, III , Benjamin R. Yerxa , Sammy R. Shaver , Ward M. Peterson , Edward G. Brown , Christopher S. Crean , José L. Boyer
发明人： James G. Douglass, III , Benjamin R. Yerxa , Sammy R. Shaver , Ward M. Peterson , Edward G. Brown , Christopher S. Crean , José L. Boyer
IPC分类号： A01N43/04 , A61K31/70
CPC分类号： C07H19/10 , C07H19/20
摘要： The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.
摘要翻译：本发明涉及具有二核苷酸药物益处的单核苷磷酸化合物。这些单核苷酸磷酸酯可以由已经通过在聚磷酸酯单核苷酸的末端磷酸酯上连接降解抗性取代基而被修饰的单核苷酸制成。通过连接该降解抗性的取代基，降解的稳定性与某些二核苷酸的匹配或超过某些二核苷酸。本发明的单核苷磷酸化合物可用于预防和治疗与血小板聚集有关的上皮组织疾病或疾病或病症。

7. 发明授权

US07132410B2 Di(uridine 5′-)tetraphosphate and salts thereof 有权
标题翻译：二（尿苷5' - ）四磷酸及其盐
公开(公告)号：US07132410B2
公开(公告)日：2006-11-07
申请号：US11055170
申请日：2005-02-09
申请人： Benjamin R. Yerxa , Edward G. Brown
发明人： Benjamin R. Yerxa , Edward G. Brown
IPC分类号： C07H21/00 , A61K37/70
CPC分类号： A61K31/7048 , A61K31/7068 , A61K31/7072 , A61K31/7076 , C07H19/10 , C07H19/20 , C07H21/00 , Y10S514/851
摘要： The present invention are directed to P1, P4-di(uridine 5′-)tetraphosphate, tetra-alkali metal salts such as tetrasodium, tetralithium, tetrapotassium, and mixed tetra-alkali metal cations thereof. The tetra alkali metal salts of P1, P4-di(uridine 5′-)tetraphosphate are water-soluble, nontoxic, and easy to handle during manufacture. These tetra-monovalent alkali metal salts are more resistant to hydrolysis than the mono-, di-, or tri-acid salts, therefore, they provide an improved stability and a longer shelf life for storage. The present invention also provides methods for the synthesis of P1, P4-di(uridine 5′-)tetraphosphate, and its pharmaceutically acceptably acceptable salts thereof, and demonstrates the applicability to the production of large quantities. The methods substantially reduce the time required to synthesize diuridine tetraphosphate, for example, to three days or less.
摘要翻译：本发明涉及P 1，P 4 - 二（尿苷5'-）四磷酸盐，四碱金属盐如四钠，四锂，四钾，并混合其四碱金属阳离子。 P 1，4 -di（尿苷5'-）四磷酸的四碱金属盐是水溶性的，无毒的，并且在制造过程中易于处理。这些四价一价碱金属盐比单 - ，二 - 或三 - 酸盐更耐水解，因此，它们提供了改进的稳定性和更长的储存期限。本发明还提供了合成P 1，P 4 - 二（尿苷5' - ）四磷酸及其药学上可接受的盐的方法，并且证明了适用于大批量生产。所述方法基本上减少了合成二脯氨酸四磷酸酯所需的时间，例如为3天或更短。

8. 发明授权

US07109181B2 Joint lubrication with P2Y purinergic receptor agonists 有权
公开(公告)号：US07109181B2
公开(公告)日：2006-09-19
申请号：US10183320
申请日：2002-06-25
申请人： Matthew S. Cowlen , Benjamin R. Yerxa , Arthur C. Jones , Edward G. Brown
发明人： Matthew S. Cowlen , Benjamin R. Yerxa , Arthur C. Jones , Edward G. Brown
IPC分类号： A61K31/70 , A61K31/66
CPC分类号： C07H19/10 , A61K31/00 , A61K31/675 , A61K31/706 , A61K31/7072 , A61K31/7076 , A61K31/728 , A61K45/06 , C07H19/20 , A61K2300/00
摘要： The present invention is directed to a method of altering the amount or composition of synovial fluids secreted from joints in a subject in need of such treatment. The method comprises administering to a subject a pharmaceutical composition comprising a P2Y purinergic receptor agonist in an amount effective to alter the amount or composition of synovial fluids. The P2Y purinergic receptor agonist is administered in an amount effective to stimulate secretion of synovial fluid, lubricin, hyaluronic acid, or surface-active phospholipids; to enhance joint lubrication; or to treat osteoarthritis. The pharmaceutical compositions useful in the present invention comprise a P2Y purinergic receptor agonist of Formula I and include, but are not limited to: uridine-, adenosine-, cytidine-5′-di- or triphosphates, dinucleoside polyphosphates, and analogs thereof. The invention is useful for treating conditions associated with reduced joint lubrication and joint stiffness, such as osteoarthritis.

9. 发明授权

US06897201B2 Compositions and methods for the treatment of glaucoma or ocular hypertension 失效
标题翻译：用于治疗青光眼或高眼压症的组合物和方法
公开(公告)号：US06897201B2
公开(公告)日：2005-05-24
申请号：US10087551
申请日：2002-02-27
申请人： Jose L. Boyer , Benjamin R. Yerxa , Robert Plourde, Jr. , Edward G. Brown
发明人： Jose L. Boyer , Benjamin R. Yerxa , Robert Plourde, Jr. , Edward G. Brown
IPC分类号： A61K31/7068 , A61K31/7072 , A61K31/7084 , A61K31/7125 , A61P27/00 , A61P27/06 , C07H19/04 , C07H19/10 , C07H19/20 , C07H19/207 , C07H21/00 , A61K31/70 , A01N43/04
CPC分类号： A61K31/7084 , A61K31/7068 , A61K31/7072 , C07H19/04 , C07H19/10 , C07H19/20 , C07H19/207 , C07H21/00
摘要： The present invention is directed to a method of reducing intraocular pressure. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a nucleoside 5′-pyrophosphate pyranoside or analogue, which is defined by general Formula I. The method of the present invention is useful in the treatment or prevention of ocular hypertension, such as found in glaucoma, including primary and secondary glaucoma. The method can be used alone to reduce intraocular pressure. The method can also be used in conjunction with another therapeutic agent or adjunctive therapy commonly used to treat glaucoma to enhance the therapeutic effect of reducing the intraocular pressure. The present invention also provides a novel composition comprising a nucleoside 5′-pyrophosphate pyranoside or analogues.
摘要翻译：本发明涉及降低眼内压的方法。该方法包括向受试者施用包含有效量的由通式I定义的核苷5'-焦磷酸吡喃糖苷或类似物的药物组合物。本发明的方法可用于治疗或预防高眼压症，例如在青光眼中发现，包括原发性和继发性青光眼。该方法可单独使用以降低眼内压。该方法还可以与通常用于治疗青光眼的另一种治疗剂或辅助治疗联合使用，以增强降低眼内压的治疗效果。本发明还提供了包含核苷5'-焦磷酸吡喃糖苷或类似物的新型组合物。

10. 发明申请

US20090076256A1 DEGRADATION-RESISTANT MONONUCLEOSIDE PHOSPHATE COMPOUNDS 失效
标题翻译：耐腐蚀单核苷酸磷酸酯化合物
公开(公告)号：US20090076256A1
公开(公告)日：2009-03-19
申请号：US12208265
申请日：2008-09-10
申请人： James G. Douglass, III , Benjamin R. Yerxa , Sammy R. Shaver , Ward M. Peterson , Edward G. Brown , Christopher S. Crean , Jose L. Boyer
发明人： James G. Douglass, III , Benjamin R. Yerxa , Sammy R. Shaver , Ward M. Peterson , Edward G. Brown , Christopher S. Crean , Jose L. Boyer
IPC分类号： C07H19/20
CPC分类号： C07H19/10 , C07H19/20
摘要： The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.
摘要翻译：本发明涉及具有二核苷酸药物益处的单核苷磷酸化合物。这些单核苷酸磷酸酯可以由已经通过在聚磷酸酯单核苷酸的末端磷酸酯上连接降解抗性取代基而被修饰的单核苷酸制成。通过连接该降解抗性的取代基，降解的稳定性与某些二核苷酸的匹配或超过某些二核苷酸。本发明的单核苷磷酸化合物可用于预防和治疗与血小板聚集有关的上皮组织疾病或疾病或病症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式